GlassScriptPhysician profile
Allen B King
NPI 1649253048
$3,672.68
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $2,525 · 2021: $727 · 2022: $199 · 2024: $20.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,099.36 | 2020-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.58 | 2019-2022 | |
| Lilly USA, LLC | $358.62 | 2019-2021 | |
| Abbott Laboratories | $178.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $116.94 | 2021-2022 | |
| Insulet Corporation | $102.33 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $101.24 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $77.39 | 2021-2022 | |
| Medtronic Minimed, INC. | $55.02 | 2020 | |
| Lifescan, INC. | $36.49 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Dexcom, INC. | $17.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.89 | 2019 | |
| Mannkind Corporation | $15.76 | 2019 | |
| Becton, Dickinson and Company | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.